What these scores mean before diving into the numbers

Two scoring systems appear repeatedly in ChondroFiller research, and understanding what each one actually measures makes the numbers far easier to interpret.

IKDC — the International Knee Documentation Committee score — is a questionnaire completed by the patient. It covers 18 questions about pain, stiffness, swelling, and the ability to perform everyday and sporting activities, producing a total out of 100. A score of 100 represents a fully symptom-free knee; a score near zero reflects severe limitation. Because patients fill it in themselves, it captures precisely what clinicians most want to know: does this person feel meaningfully better?

That question has a measurable answer. Research has established that the Minimal Clinically Important Difference (MCID) for the IKDC is 16.7 points — the minimum gain at which most patients reliably notice a change in their daily life. Improvements below that threshold may appear on paper without the patient actually feeling them; improvements above it represent genuine, lived benefit.

MOCART approaches recovery from a different angle entirely. Rather than asking the patient anything, it analyses MRI scans to rate how completely the cartilage defect has filled, how well new tissue integrates with the surrounding native cartilage, and what the signal characteristics of that repair tissue look like. It also runs from 0 to 100, with higher scores indicating more structurally robust repair.

The two tools are reported together in ChondroFiller studies for a practical reason: a reassuring MRI does not automatically mean the patient feels well, and a high patient score does not guarantee complete defect fill. Tracking both gives a fuller picture of recovery than either could alone.

ChondroFiller itself is an injectable collagen scaffold that works through acellular matrix-induced chondrogenesis — once placed into the defect under ultrasound guidance, it gels in situ and draws the patient's own progenitor cells in from the surrounding tissue, rather than delivering cells directly. That biological process is what both scores are ultimately monitoring.

IKDC at 12 months: how much function patients regain

The IKDC data across ChondroFiller studies tells a clear story. Patients entering treatment typically score around 48 — placing them in the moderate-to-significant limitation band, where stairs, sustained walking, and most sporting activity cause noticeable difficulty.

By 12 months, the mean score across four prospective knee cartilage studies synthesised in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025) has climbed to approximately 80 — a gain of roughly 30 points. That figure is close to double the 16.7-point MCID, putting the improvement squarely in territory patients feel in daily life rather than a shift visible only on a spreadsheet. The trajectory is consistent across European multicentre data and an independent 2016 prospective randomised multicentre trial, which recorded statistically significant IKDC improvement from pre-operative values at three and six months (p<0.05), maintained through to 12 months — so this is not a single-centre finding.

An independent 2024 knee cohort of 17 patients (mean age 31) adds an important detail about timing. Significant improvement was recorded at three, six, and 12 months, but no statistically significant further rise occurred between the six- and 12-month readings. This is best understood as consolidation at a high functional level rather than a ceiling: a score of around 80 corresponds to comfortable everyday activity and recreational sport, and stabilising there is a positive endpoint. Much of the recovery of knee function occurs in the first half of the year; the second half confirms and anchors it.

MOCART at 12 months: what the MRI shows about repair tissue

MRI tells a different story from the patient questionnaire — and on a different timetable.

Four weeks after the ultrasound-guided injection, early MOCART readings in one key study averaged 65.3. The scaffold has formed and begun integrating, but the repair tissue is still maturing. By 12 months, that figure rises to a stable range of 81.6 to 84.3 across European ChondroFiller knee studies synthesised in the manufacturer's Clinical Evaluation Report (CER Version 09, April 2025). The 2016 prospective randomised multicentre trial independently documents the same trajectory: good immediate defect fill at four weeks, followed by impressive cartilage maturation confirmed by 52 weeks.

In structural terms, a MOCART above 80 means the defect is more than 80% filled and the edges of the repair tissue integrate well with the surrounding native cartilage — what radiologists describe as good border integration. That is a clinically robust result, not a borderline one.

A useful reference point from the broader cartilage repair literature: a study of 86 patients with tibiofemoral lesions identifies a MOCART 2.0 threshold of 60 or above at one year as predictive of favourable patient-reported outcomes including IKDC and Lysholm. ChondroFiller results in European studies sit approximately 20 to 24 points above that benchmark.

There is also a notable temporal offset between the two measures. Whereas patient-reported function largely consolidates by six months, MOCART scores continue to climb progressively through the full first year. Structural maturation on MRI continues independently of — and after — the functional recovery the patient has already experienced.

Does the improvement last? The 36-month picture

For most patients, the question that follows early results is the practical one: will it last?

The three-year data from the Jerosch et al. post-market clinical follow-up (PMCF) study suggest it does. Mean IKDC at 36 months stands at 80.1 — sustained or fractionally increased from the 12-month level rather than eroded. MOCART scores at the same point remain in the good-to-excellent range, with no meaningful structural decline relative to the one-year MRI findings.

That pattern — early functional gain, consolidation around six months, and durable maintenance at three years — is not universal in cartilage repair. Some treatments show progressive degradation of effect as repair tissue fails to withstand ongoing joint loading; a score that retreats from its peak year-on-year implies mechanically inferior tissue. ChondroFiller's three-year picture does not show that retreat.

The biological basis for this durability rests on what happens during scaffold-driven repair. Acellular matrix-induced chondrogenesis draws the patient's own progenitor cells into the defect, where they progressively deposit repair tissue over weeks and months. Ex vivo data quantify that recruitment directly: DNA content rises 2.4-fold by day 14, confirming that the scaffold activates a sustained cellular response rather than simply filling the space temporarily. Tissue built through active progenitor cell recruitment carries greater structural integrity than a passive mechanical plug, which is the most plausible explanation for why the functional gains appear stable rather than transient.

The three-year data derive primarily from one prospective PMCF study, and large randomised trials with follow-up beyond that point have not yet been completed. The existing evidence is prospective and the trajectory consistent across studies — a reasonable basis for clinical confidence, while leaving scope for longer follow-up to consolidate the picture further.

How IKDC and MOCART relate — and where they diverge

A study of 111 patients across 188 MRI evaluations puts a number on the relationship: MOCART and IKDC correlate at r=0.837 in cross-sectional data, confirming that at a population level the two measures broadly track the same underlying process. When repair tissue looks structurally sound across a group of patients, those patients tend to report better function — the scores move together.

The important caveat sits one level down. Cross-sectional agreement across a sample does not mean that a rising MOCART reliably predicts a greater patient-felt improvement for any specific individual. The same research found no significant correlation between either score and changes in patient-reported outcomes — the direction and magnitude of a particular patient's functional recovery cannot simply be read off their MRI reading. Population patterns and individual trajectories are different problems, and conflating them can lead clinicians to over-weight structural imaging at the expense of what the patient actually experiences.

The temporal offset noted in the MOCART trajectory adds a further layer. Structural maturation on MRI continues through the full first year, whereas functional recovery largely consolidates by six months. A patient reporting strong IKDC scores before their one-year scan is not contradicting the imaging; the two measures are running on different clocks.

For clinicians, this means MOCART alone is insufficient grounds for declaring success or failure — patient-reported IKDC remains the primary functional marker. For patients, a scan showing maturing repair tissue and a questionnaire showing improved function represent two complementary windows onto one recovery: most informative when read side by side.

Who is most likely to benefit and what the evidence gaps are

Patient selection shapes outcomes at least as much as the treatment itself — and the evidence is clear on where the boundaries lie.

The strongest data come from knee studies. In hip arthroscopy, a cohort of 26 patients followed for 12 to 60 months showed 17 of 21 evaluable patients reaching good or excellent results, which is encouraging. The important qualification is that patients with pre-existing osteoarthritis graded Tönnis 2–3 did poorly. That finding points to a consistent selection principle across joints: ChondroFiller is indicated for focal cartilage defects in a joint with broadly intact surrounding tissue, not for generalised degeneration. The scaffold needs a healthy biological environment to recruit progenitor cells effectively; compromised or thinned neighbouring cartilage undermines that process.

Technique matters too. Overfilling the defect — placing more scaffold than the lesion depth requires — is associated with fibrous rather than hyaline-like repair tissue formation. Flush application, matched precisely to the defect dimensions under image guidance, produces structurally superior repair. This is a quality consideration directly relevant to ultrasound-guided placement.

On the evidence side, two gaps are worth naming plainly. The combined NanoACi protocol — ChondroFiller alongside micrografts and platelet-rich fibrin — draws on component-level evidence for each element individually, but has not been validated as a complete three-part protocol in a randomised controlled trial. Separately, large head-to-head RCTs comparing ChondroFiller with microfracture or autologous chondrocyte implantation over multi-year follow-up remain absent from the published literature. That absence is not unique to this product — long-term cartilage RCTs are a recognised gap across the field — but it is worth stating clearly when evaluating the three-year data that do exist.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Correlation and Comparative Evaluation of MOCART and MOCART 2.0 for Assessing Cartilage Repair. (2025). https://doi.org/10.3390/medicina61040745 https://doi.org/10.3390/medicina61040745
3. [3] Controlled, randomized multicenter study to compare compatibility and safety of ChondroFiller liquid with microfracturing in focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
5. [5] MOCART 2.0 score of 60 or greater measured at 1 year post-operatively predicts favourable clinical outcomes after surgical repair of tibiofemoral cartilage lesions. (2025). https://doi.org/10.1002/ksa.70086 https://doi.org/10.1002/ksa.70086
6. [6] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
7. [7] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z